Table 2.

Estimated Pharmacokinetic Parameters of RBZ and 10×RBZ after Intravitreal Injection into New Zealand White Rabbits

	t 1/2 (h)	MRT (h)	Cmax (µg/mL)	Tmax (h)	AUC (h × µg/mL)	V/F (mL)	CL/F (mL/h)
Anterior chamber
RBZ 0.3 mg/0.03 mL	55.58 ± 7.72	171.04 ± 19.82	23.08	1	3431.81	7.01	0.087
10×RBZ 3.0 mg/0.03 mL	53.36 ± 5.14	138.03 ± 15.19	181.48	1	23.020.1	10.03	0.130
Vitreous
RBZ 0.3 mg/0.03 mL	51.70 ± 6.03	81.59 ± 7.48	140.01	1	12,202.52	1.81	0.024
10×RBZ 3.0 mg/0.03 mL	52.60 ± 4.86	131.28 ± 10.67	1637.54	1	198,715.6	1.15	0.015
Retina
RBZ 0.3 mg/0.03 mL	36.74 ± 3.79	107.19 ± 9.32	102.70	24	16,491.45	0.96	0.018
10×RBZ 3.0 mg/0.03 mL	76.85 ± 6.63	140.51 ± 11.37	224.68	96	34,656.53	9.58	0.086
Serum
RBZ 0.3 mg/0.03 mL	91.93 ± 7.75	252.73 ± 18.46	7.35 × 10−3	24	1644.41 × 10−3	21.85 × 103	0.164 × 103
10×RBZ 3.0 mg/0.03 mL	179.01 ± 15.09	479.98 ± 31.25	22.07 × 10−3	24	6885.24 × 10−3	103.73 × 103	0.401 × 103

AUC, area under concentration-time curve; CL/F, apparent clearance; C_max, observed maximum concentration; MRT, mean residence time; 10×RBZ, 10-fold ranibizumab; RBZ, ranibizumab; t_1/2, half-life; T_max, time to C_max; V/F, apparent volume of distribution.